|
WO2017139708A1
|
|
Bacteria engineered to treat nonalcoholic steatohepatitis (nash)
|
|
WO2017139697A1
|
|
Bacteria engineered to treat diseases associated with hyperammonemia
|
|
WO2017136795A1
|
|
Bacteria engineered to treat diseases associated with tryptophan metabolism
|
|
WO2017123676A1
|
|
Recombinant bacteria engineered to treat diseases and disorders associated with amino acid metabolism and methods of use thereof
|
|
US2019160115A1
|
|
Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
|
|
WO2017123592A1
|
|
Bacteria engineered to treat disorders associated with bile salts
|
|
WO2017123610A2
|
|
Bacteria engineered to detoxify deleterious molecules
|
|
US2019282628A1
|
|
Recombinant bacteria engineered to treat diseases and disorders associated with amino acid metabolism and methods of use thereof
|
|
US2017216370A1
|
|
Bacteria engineered to treat disorders involving propionate catabolism
|
|
US2019010506A1
|
|
Bacteria engineered to treat metabolic diseases
|
|
WO2017123418A1
|
|
Bacteria engineered to treat metabolic diseases
|
|
WO2017075485A1
|
|
Bacteria engineered to treat disorders in which trimethylamine (tma) is detrimental
|
|
US2018325963A1
|
|
Bacteria engineered to treat disorders in which oxalate is detrimental
|
|
EP3313371A2
|
|
Bacteria engineered to treat metabolic diseases
|
|
WO2016210373A2
|
|
Recombinant bacteria engineered for biosafety, pharmaceutical compositions, and methods of use thereof
|
|
WO2016210378A2
|
|
Multi-layered control of gene expression in genetically engineered bacteria
|
|
CA2988981A1
|
|
Bacteria engineered to treat disorders involving the catabolism of a branched chain amino acid
|
|
US2016333326A1
|
|
Bacteria engineered to treat diseases associated with hyperammonemia
|
|
EP3294757A1
|
|
Bacteria engineered to treat a disease or disorder
|
|
BR112017024384A2
|
|
bacteria modified to reduce hyperphenylalaninemia
|
